Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck
ConclusionCetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Erbitux | Head and Neck Cancer | HNSCC | Skin Cancer | Squamous Cell Carcinoma | Study | Thrombocytopenia